Clinical Trial

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-26; most recent amendment 2025-11-18.
Trial Details
NCT Number NCT07146022
Lead Sponsor Veradermics, Inc.
Conditions Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Enrollment 552 participants
Start Date 2025-07-25
Primary Completion 2027-06 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-24